Efficacy of immune-oncology combinations versus sunitinib in patients with bone metastases from renal cell carcinoma: A systematic review and meta-analysis of phase III trials with long-term follow-up.
Immune-based cancer combinations appear more effective than standard therapy for kidney cancer patients with bone metastases.
This systematic review and meta-analysis of phase iii trials examined efficacy of immune-oncology combinations versus sunitinib in patients with bone metastases from renal cell carcinoma: a systematic review and meta-analysis of phase iii trials with long-term follow-up. The abstract reports that these findings suggest that treatment strategy may influence outcomes in this high-risk subgroup.
What the study was
- Study design
- Systematic review and meta-analysis of phase III trials
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Journal of bone oncology
Why it surfaced
Systematic review and meta-analysis of phase III trials relevant to Novel therapeutics: immunotherapy, CAR-T, targeted therapy; score assigned conservatively from the PubMed abstract and metadata.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.